Delcath Systems to Participate in Upcoming Investor Conferences
July 30 2024 - 4:01PM
Business Wire
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology
company focused on the treatment of primary and metastatic cancers
of the liver, today announced that management will be attending the
following upcoming investor conferences:
BTIG Virtual Biotechnology Conference Date: Tuesday,
August 6, 2024 Location: Virtual
Canaccord Genuity's 44th Annual Growth Conference Date:
Wednesday, August 14, 2024 Presentation Time: 9:30 am Eastern Time
Location: Boston, MA
About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT
Delcath Systems, Inc. is an interventional oncology company
focused on the treatment of primary and metastatic liver cancers.
The company's proprietary products, HEPZATO KIT™ (Hepzato
(melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT®
Hepatic Delivery System for Melphalan percutaneous hepatic
perfusion (PHP), are designed to administer high-dose chemotherapy
to the liver while controlling systemic exposure and associated
side effects during a PHP procedure.
In the United States, HEPZATO KIT is considered a combination
drug and device product and is regulated and approved for sale as a
drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic
drug melphalan and Delcath's proprietary Hepatic Delivery System
(HDS). The HDS is used to surgically isolate the liver while
simultaneously filtrating hepatic venous blood during melphalan
infusion and washout. The use of the HDS results in loco-regional
delivery of a relatively high melphalan dose, which can potentially
induce a clinically meaningful tumor response with minimal
hepatotoxicity and reduce systemic exposure. HEPZATO KIT is
approved in the United States as a liver-directed treatment for
adult patients with metastatic uveal melanoma (mUM) with
unresectable hepatic metastases affecting less than 50% of the
liver and no extrahepatic disease, or extrahepatic disease limited
to the bone, lymph nodes, subcutaneous tissues, or lung that is
amenable to resection or radiation. Please see the full Prescribing
Information, including BOXED WARNING for the HEPZATO KIT.
In Europe, the device-only configuration of the HDS is regulated
as a Class III medical device and is approved for sale under the
trade name CHEMOSAT Hepatic Delivery System for Melphalan, or
CHEMOSAT, where it has been used in the conduct of percutaneous
hepatic perfusion procedures at major medical centers to treat a
wide range of cancers of the liver.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240730402570/en/
Investor Relations: ICR Westwicke
investorrelations@delcath.com
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Delcath Systems (NASDAQ:DCTH)
Historical Stock Chart
From Sep 2023 to Sep 2024